Literature DB >> 23204476

Primetime for chemotherapy in acute myeloid leukemia.

Jan Cools.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23204476      PMCID： PMC3590079          DOI： 10.3324/haematol.2012.081414

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.

Authors:  Alison Walker; Guido Marcucci
Journal:  Haematologica       Date:  2011-05       Impact factor: 9.941

2.  RNAi screening of the kinome with cytarabine in leukemias.

Authors:  Raoul Tibes; James M Bogenberger; Leena Chaudhuri; R Tanner Hagelstrom; Donald Chow; Megan E Buechel; Irma M Gonzales; Tim Demuth; James Slack; Ruben A Mesa; Esteban Braggio; Hongwei H Yin; Shilpi Arora; David O Azorsa
Journal:  Blood       Date:  2012-01-20       Impact factor: 22.113

3.  The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.

Authors:  Elisabeth J Walsby; Steven J Coles; Steven Knapper; Alan K Burnett
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

4.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

5.  The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Authors:  Versha Banerji; Stacey M Frumm; Kenneth N Ross; Loretta S Li; Anna C Schinzel; Cynthia K Hahn; Rose M Kakoza; Kwan T Chow; Linda Ross; Gabriela Alexe; Nicola Tolliday; Haig Inguilizian; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; Giovanni Roti; Jon C Aster; William C Hahn; Andrew L Kung; Kimberly Stegmaier
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

Review 6.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis.

Authors:  Anthony G Letai
Journal:  Nat Rev Cancer       Date:  2008-02       Impact factor: 60.716

7.  Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Authors:  Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jing Deng; Adrian Wiestner; Brian J Lannutti; Lili Wang; Catherine J Wu; Wyndham H Wilson; Jennifer R Brown; Anthony Letai
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

10.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Authors:  Johannes Zuber; Junwei Shi; Eric Wang; Amy R Rappaport; Harald Herrmann; Edward A Sison; Daniel Magoon; Jun Qi; Katharina Blatt; Mark Wunderlich; Meredith J Taylor; Christopher Johns; Agustin Chicas; James C Mulloy; Scott C Kogan; Patrick Brown; Peter Valent; James E Bradner; Scott W Lowe; Christopher R Vakoc
Journal:  Nature       Date:  2011-08-03       Impact factor: 49.962
View more
  1 in total

1.  Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.

Authors:  Angélica Cuapio; Mirte Post; Sabine Cerny-Reiterer; Karoline V Gleixner; Gabriele Stefanzl; Jose Basilio; Susanne Herndlhofer; Wolfgang R Sperr; Nicolaas H C Brons; Emilio Casanova; Jacques Zimmer; Peter Valent; Erhard Hofer
Journal:  Oncotarget       Date:  2016-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.